Aderis Pharmaceuticals, Inc.
Records under this name other than patents Aderis Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Aderis Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,251,844 | Transdermal Therapeutic System and Method of Use Thereof for Treating Parkinsonism Formerly held Term ended Ended no later than Feb 25, 2024 · Low confidence | Term ended | Ended no later than Feb 25, 2024 | Low confidence |
| US 10,322,093 | Method for Producing a Transdermal Therapeutic System Which Contains a D2 Agonist Formerly held Term ended Term ended Sep 22, 2022 · Medium confidence | Term ended | Term ended Sep 22, 2022 | Medium confidence |
| US 6,884,434 | Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof Formerly held Term ended Term ended Mar 30, 2021 · From the USPTO record | Term ended | Term ended Mar 30, 2021 | From the USPTO record |
| US 6,372,920 | Process for preparing nitrogen-substituted aminotetralins Formerly held Term ended Term ended Nov 16, 2020 · From the USPTO record | Term ended | Term ended Nov 16, 2020 | From the USPTO record |
| US 7,413,747 | Transdermal Therapeutic System for Treating Parkinsonism Formerly held Term ended Ended no later than Mar 18, 2019 · Low confidence | Term ended | Ended no later than Mar 18, 2019 | Low confidence |
| US RE37,045 | N-6 substituted-5'-(N-substituted carboxamide)adenosines as cardiac vasodilator and antihypertensive agents Term ended Term ended Jan 21, 2019 · From the USPTO record | Term ended | Term ended Jan 21, 2019 | From the USPTO record |
| US RE36,494 | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents Term ended Term ended Jan 11, 2017 · From the USPTO record | Term ended | Term ended Jan 11, 2017 | From the USPTO record |
| US 6,372,723 | Compositions and methods for preventing restenosis following revascularization procedures Lapsed on the fee record Ended Apr 16, 2010 · From the USPTO record | Lapsed on the fee record | Ended Apr 16, 2010 | From the USPTO record |
| US 6,339,072 | Compositions and methods for preventing restenosis following revascularization procedures Lapsed on the fee record Ended Jan 15, 2010 · From the USPTO record | Lapsed on the fee record | Ended Jan 15, 2010 | From the USPTO record |
| US 6,784,165 | Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines Lapsed on the fee record Ended Aug 31, 2008 · From the USPTO record | Lapsed on the fee record | Ended Aug 31, 2008 | From the USPTO record |